Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes

International Journal of Antimicrobial Agents

Volumn 34, Issue 3, 2009, Pages 236-239

  Ruan, Sheng Yuan ^a   Huang, Yu Tsung ^a   Chu, Chen Chen ^a   Yu, Chong Jen ^a   Hsueh, Po Ren ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antifungal susceptibility; Candida glabrata; Candidaemia; Fungaemia; Outcome

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUNGUS ISOLATION; HEALTH CENTER; HUMAN; INFECTION RISK; INTRAVENOUS CATHETER; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 66949138367     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.02.021     Document Type: Article

References (32)

1. Asmundsdottir L.R., Erlendsdottir H., and Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 40 (2002) 3489-3492
2. Beck-Sague C., and Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 167 (1993) 1247-1251
3. Hsueh P.R., Teng L.J., Yang P.C., Ho S.W., and Luh K.T. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb Drug Resist 8 (2002) 311-319
4. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100 (1996) 617-623
5. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., and Gaynes R.P. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35 (2002) 627-630
6. Sandven P., Bevanger L., Digranes A., Haukland H.H., Mannsaker T., and Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 44 (2006) 1977-1981
7. Pfaller M.A., and Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 10 Suppl. 1 (2004) 11-23
8. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20 (2007) 133-163
9. Eggimann P., Garbino J., and Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3 (2003) 685-702
10. Fidel P.L., Vazquez J.A., and Sobel J.D. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12 (1999) 80-96
11. National Committee for Clinical Laboratory Standards. Reference method for broth microdilution antifungal susceptibility testing of yeasts; approved standard. Document M27-A2 (2002), NCCLS, Wayne, PA
12. Nguyen M.H., Clancy C.J., Yu V.L., Yu Y.C., Morris A.J., Snydman D.R., et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 177 (1998) 425-430
13. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008) 150-156
14. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 44 (2006) 819-826
15. AbiSaid D., Anaissie E., Uzun O., Raad I., Pinzcowski H., and Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24 (1997) 1122-1128
16. Safdar A., Chaturvedi V., Cross E.W., Park S., Bernard E.M., Armstrong D., et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 45 (2001) 2129-2133
17. Hachem R., Hanna H., Kontoyiannis D., Jiang Y., and Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112 (2008) 2493-2499
18. Marr K.A., Seidel K., White T.C., and Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181 (2000) 309-316
19. Lin M.Y., Carmeli Y., Zumsteg J., Flores E.L., Tolentino J., Sreeramoju P., et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 49 (2005) 4555-4560
20. Gumbo T., Isada C.M., Hall G., Karafa M.T., and Gordon S.M. Candida glabrata fungemia-clinical features of 139 patients. Medicine 78 (1999) 220-227
21. Malani A., Hmoud J., Chiu L., Carver P.L., Bielaczyc A., and Kauffman C.A. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 41 (2005) 975-981
22. Boo T.W., O'Reilly B., O'Leary J., and Cryan B. Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. Mycoses 48 (2005) 251-259
23. Uzun O., and Anaissie E.J. Predictors of outcome in cancer patients with candidemia. Ann Oncol 11 (2000) 1517-1521
24. Weinberger M., Leibovici L., Perez S., Samra Z., Ostfeld I., Levi I., et al. Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 61 (2005) 146-154
25. Nucci M., and Anaissie E. Revisiting the source of candidemia: skin or gut?. Clin Infect Dis 33 (2001) 1959-1967
26. Antoniadou A., Torres H.A., Lewis R.E., Thornby J., Bodey G.P., Tarrand J.J., et al. Candidemia in a tertiary care cancer center-in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 82 (2003) 309-321
27. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37 (2003) 634-643
28. Viudes A., Peman J., Canton E., Ubeda P., Lopez-Ribot J.L., and Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21 (2002) 767-774
29. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
30. Wilson A.G., Micek S.T., and Ritchie D.J. A retrospective evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clin Ther 27 (2005) 1228-1237
31. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 (2006) 25-31
32. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49 (2005) 3640-3645